Wells Fargo & Company Akebia Therapeutics, Inc. Transaction History

Wells Fargo & Company

$433 Billion
Q4 2024

A detailed history of Wells Fargo & Company transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 122,397 shares of AKBA stock, worth $257,033. This represents 0.0% of its overall portfolio holdings.

Number of Shares

122,397

Previous 99,298 23.26%

Holding current value

$257,033

Previous $131,000 73.28%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$1.26 - $2.13 $29,104 - $49,200	23,099 Added 23.26%	122,397 $227,000
Q3 2024 Nov 13, 2024	BUY	$0.94 - $1.55 $3,007 - $4,958	3,199 Added 3.33%	99,298 $131,000
Q2 2024 Aug 13, 2024	BUY	$0.86 - $1.63 $75,729 - $143,532	88,057 Added 1094.96%	96,099 $98,000
Q1 2024 May 10, 2024	SELL	$1.27 - $2.24 $3,878 - $6,840	-3,054 Reduced 27.52%	8,042 $14,000
Q4 2023 Feb 09, 2024	BUY	$0.8 - $1.28 $66 - $106	83 Added 0.75%	11,096 $13,000
Q3 2023 Nov 13, 2023	SELL	$0.87 - $1.84 $102 - $217	-118 Reduced 1.06%	11,013 $12,000
Q2 2023 Aug 15, 2023	SELL	$0.51 - $1.43 $577 - $1,620	-1,133 Reduced 9.24%	11,131 $10,000
Q1 2023 May 12, 2023	SELL	$0.56 - $1.15 $680 - $1,397	-1,215 Reduced 9.01%	12,264 $6,000
Q4 2022 Feb 13, 2023	SELL	$0.25 - $0.58 $83 - $194	-335 Reduced 2.43%	13,479 $7,000
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.46 $342 - $525	-1,142 Reduced 7.64%	13,814 $4,000
Q2 2022 Aug 12, 2022	SELL	$0.32 - $0.67 $89,816 - $188,053	-280,677 Reduced 94.94%	14,956 $4,000
Q1 2022 May 16, 2022	SELL	$0.72 - $2.93 $37,670 - $153,297	-52,320 Reduced 15.04%	295,633 $212,000
Q4 2021 Feb 14, 2022	BUY	$2.26 - $3.34 $456,843 - $675,157	202,143 Added 138.63%	347,953 $787,000
Q3 2021 Nov 15, 2021	BUY	$2.35 - $3.88 $296,473 - $489,496	126,159 Added 642.0%	145,810 $421,000
Q2 2021 Aug 16, 2021	SELL	$2.83 - $4.2 $251,145 - $372,724	-88,744 Reduced 81.87%	19,651 $75,000
Q1 2021 May 13, 2021	SELL	$2.92 - $5.06 $444,748 - $770,693	-152,311 Reduced 58.42%	108,395 $367,000
Q4 2020 Feb 09, 2021	SELL	$2.22 - $3.78 $113,628 - $193,475	-51,184 Reduced 16.41%	260,706 $730,000
Q3 2020 Nov 05, 2020	BUY	$2.39 - $13.08 $13,305 - $72,816	5,567 Added 1.82%	311,890 $782,000
Q2 2020 Aug 13, 2020	BUY	$6.67 - $13.58 $426,679 - $868,712	63,970 Added 26.4%	306,323 $4.16 Million
Q1 2020 May 14, 2020	BUY	$4.1 - $10.24 $993,647 - $2.48 Million	242,353 New	242,353 $1.84 Million

Others Institutions Holding AKBA

# of Institutions

128

Shares Held

63.3M

Call Options Held

50.6K

Put Options Held

203K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $386M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Akebia Therapeutics, Inc. Transaction History